about
Population pharmacokinetics of meropenem during continuous infusion in surgical ICU patients.Meropenem versus cefuroxime plus gentamicin for treatment of serious infections in elderly patients.Single-dose pharmacokinetics of meropenem during continuous venovenous hemofiltration.Noncompromised penicillin-resistant pneumococcal pneumonia CBA/J mouse model and comparative efficacies of antibiotics in this model.Meropenem in the treatment of complicated skin and soft tissue infectionsSaMpling Antibiotics in Renal Replacement Therapy (SMARRT): an observational pharmacokinetic study in critically ill patientsSynthesis, pH-dependent, and plasma stability of meropenem prodrugs for potential use against drug-resistant tuberculosisPharmacological aspects of the antibiotics used for urological diagnostic procedures.Population pharmacokinetics of meropenem in elderly patients: dosing simulations based on renal function.Population pharmacokinetic analysis of meropenem in Japanese adult patients.Differences in antimicrobial drug exposure in patients with various degrees of renal function based on recommendations from dosing references.Pharmacokinetics of meropenem 0.5 and 2 g every 8 hours as a 3-hour infusion.Use of Monte Carlo simulation to design an optimized pharmacodynamic dosing strategy for meropenem.Meropenem and continuous renal replacement therapy: in vitro permeability of 2 continuous renal replacement therapy membranes and influence of patient renal function on the pharmacokinetics in critically ill patients.Population pharmacokinetics and pharmacodynamics of meropenem in pediatric patients.Meropenem-vaborbactam: a new weapon in the war against infections due to resistant Gram-negative bacteria.
P2860
Q30316322-7407E953-4ACD-4D21-933F-4C1A85F5D4FBQ33695881-218F29EB-0AB7-46FC-8EF9-41198DA704C5Q33697160-909BF3E7-1AD9-487F-A93D-C3E34F790B52Q35125164-B37EBC7C-A527-4414-83BB-B67F316F86FBQ35919254-F168DF6D-12A8-4627-8389-BA75DCC8CC6BQ35942407-A30D9797-A79D-413D-AD97-F5F36F8C977BQ37086328-BE5F9671-16AB-4F43-96A0-A304D54560B5Q38253258-C4926C2F-7C48-4C66-9300-8E7F09162666Q39103144-6BEE5B5D-5DA6-4176-B493-6A96E11AA7B0Q43798873-61BA3353-CD65-4822-AFDE-42FB5DB65235Q44131791-8DB4220D-F16A-41EC-946C-E05729AC1CBAQ44551301-FC4D1AA2-07ED-459D-A42D-A6356E8909ACQ44601141-0C30F712-7D28-463F-A687-83010F86F190Q46766008-C89CB5EC-7B66-4293-8E01-29A636D551A8Q46882759-2159BDF4-9352-4C8B-8DA4-16C563CA897AQ52564980-4FDC8F2D-44E1-4037-B36E-9F54BB3DD7DB
P2860
description
1995 nî lūn-bûn
@nan
1995年の論文
@ja
1995年論文
@yue
1995年論文
@zh-hant
1995年論文
@zh-hk
1995年論文
@zh-mo
1995年論文
@zh-tw
1995年论文
@wuu
1995年论文
@zh
1995年论文
@zh-cn
name
Meropenem clinical pharmacokinetics.
@en
type
label
Meropenem clinical pharmacokinetics.
@en
prefLabel
Meropenem clinical pharmacokinetics.
@en
P1476
Meropenem clinical pharmacokinetics.
@en
P2093
J N van den Anker
J W Mouton
P304
P356
10.2165/00003088-199528040-00002
P577
1995-04-01T00:00:00Z
P6179
1028300642